Drug__r.Drug_Code__c,Diagnosis__c
100extrabgts,"Not meeting glycemic targets, as determined by a physician, for 3 months or more"
100extrabgts,Acute illness or comorbidities that may impact blood glucose control
100extrabgts,"Changes in drug therapy that may impact blood glucose control (e.g., starting or stopping hypo- or hyperglycemic inducing medications, or drug-to-drug or drug-to-disease interactions)"
100extrabgts,"Occupations where hypoglycemia presents a significant safety risk (e.g., pilots, air traffic controllers, commercial drivers)"
100extrabgts,Gestational diabetes
100extrabgts,Other
1PPIpant,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
1PPIpant,Other
1PPIpant,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
1PPIpant,Zollinger-Ellison syndrome
1PPIpant,Barrett's esophagus
1PPIpant,Gastric ulcer
1PPIpant,Duodenal ulcer
1PPIpant,Gastroesophageal reflux disease (GERD)
1PPIpant,Reflux esophagitis
1PPIrabe,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
1PPIrabe,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
1PPIrabe,Barrett's esophagus
1PPIrabe,Gastric ulcer
1PPIrabe,Zollinger-Ellison syndrome
1PPIrabe,Reflux esophagitis
1PPIrabe,Gastroesophageal reflux disease (GERD)
1PPIrabe,Other
1PPIrabe,Duodenal ulcer
2PPIesom,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
2PPIesom,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
2PPIesom,Gastroesophageal reflux disease (GERD)
2PPIesom,Reflux esophagitis
2PPIesom,Other
2PPIesom,Gastric ulcer
2PPIesom,Barrett's esophagus
2PPIesom,Zollinger-Ellison syndrome
2PPIesom,Duodenal ulcer
2PPIlans,Gastroesophageal reflux disease (GERD)
2PPIlans,Reflux esophagitis
2PPIlans,Duodenal ulcer
2PPIlans,Gastric ulcer
2PPIlans,Barrett's esophagus
2PPIlans,Zollinger-Ellison syndrome
2PPIlans,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
2PPIlans,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
2PPIlans,Other
2PPIomep,Other
2PPIomep,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
2PPIomep,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
2PPIomep,Zollinger-Ellison syndrome
2PPIomep,Barrett's esophagus
2PPIomep,Gastric ulcer
2PPIomep,Duodenal ulcer
2PPIomep,Gastroesophageal reflux disease (GERD)
2PPIomep,Reflux esophagitis
2PPIpant,Previously tried Proton Pump Inhibitors - rabeprazole AND pantoprazole magnesium
2PPIpant,Other
2PPIpant,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
2PPIpant,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
2PPIpant,Zollinger-Ellison syndrome
2PPIpant,Patient has contraindications to one or more 1st line PPIs
2PPIpant,Gastric ulcer
2PPIpant,Duodenal ulcer
2PPIpant,Reflux esophagitis
2PPIpant,Gastroesophageal reflux disease (GERD)
2PPIpant,Barrett's esophagus
abatacept,Rheumatoid Arthritis
abatacept,Polyarticular Juvenile Idiopathic Arthritis (pJIA)
abatacept,Other
abobotulinum,cervical dystonia (spasmodic torticollis) in adults.
abobotulinum,focal spasticity
abobotulinum,Other
ACEIcapt,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIcapt,Other
ACEIcapt,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIcila,Other
ACEIcila,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIcila,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIdena,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIdena,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIdena,Other
ACEIenap,other
ACEIenap,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIenap,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIfosi,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIfosi,Other
ACEIfosi,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIliso,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIliso,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIliso,Other
ACEIperi,Other
ACEIperi,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIperi,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIquin,Other
ACEIquin,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIquin,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEItran,Other
ACEItran,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEItran,Requiring medication(s) for co-existing chronic condition(s)
acetaminophen,Treatment of osteoarthritis only as monotherapy.
acetaminophen,Treatment osteoarthritis as an adjunct to NSAID therapy when additional pain relief is required.
acetaminophen,Other
adalimumab,Plaque Psoriasis
adalimumab,Hidradentis Suppurativa
adalimumab,Rheumatoid Arthritis
adalimumab,Moderate to Severe Active Crohn's
adalimumab,Other
adalimumab,Psoriatic Arthritis
adalimumab,Ulcerative Colitis
adalimumab,Fistulizing Crohn's
adalimumab,Polyarticular Juvenile Idiopathic Arthritis
adalimumab,Ankylosing Spondylitis
ADHDamph,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning."
ADHDamph,Other
ADHDatom,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning."
ADHDatom,Other
ADHDlisd,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - dextroamphetamine IR/SR"
ADHDlisd,Other
ADHDlisd,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - other"
ADHDlisd,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - methylphenidate IR/SR"
ADHDmeth,"Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity, impulsivity, or inattention that interferes with functioning and - other"
ADHDmeth,Other
ADHDmeth,"Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity, impulsivity, or inattention that interferes with functioning and - dextroamphetamine IR/SR"
ADHDmeth,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - methylphenidate IR/SR"
ADTIdone,"Renewal -  mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIdone,"Initial - mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIdone,Other
ADTIgala,Other
ADTIgala,"Renewal -  mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIgala,"Initial - mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIriva,"Renewal -  mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIriva,Other
ADTIriva,"Initial - mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
afibdaba,Other
afibdaba,Patient has a diagnosis of non-valvular atrial fibrillation
aggrenox,For secondary prevention of cerebrovascular occlusion and embolization in patients who have experienced recurrent TIA OR stroke while receiving ASA alone
aggrenox,Other
alemtuzumab,As monotherapy for the treatment of relapsing-remitting multiple sclerosis
alenalen,clinical or radiographically documented fracture due to osteoporosis
alenalen,Other
alenalen,Glucocorticoid-induced osteoporosis in patients who are receiving or expected to receive the equivalent dose of 7.5 mg of prednisone per day or greater AND for 90 consecutive days or longer.
alenrise,Clinical or radiographically documented fracture due to osteoporosis
alenrise,Other
alenrise,Glucocorticoid-induced osteoporosis
alitretinoin,Other
alitretinoin,For the treatment of severe chronic hand eczema 
antiemeticgran,Prescribed for the prevention and treatment of nausea and vomiting associated with chemotherapy
antiemeticgran,Other
antiemeticonda,Other
antiemeticonda,Prevention and treatment of nausea and vomiting associated with chemotherapy
antifungalciclo,Diagnosis of a fungal infection of the lower extremities - other
antifungalciclo,Diagnosis of a fungal infection of the lower extremities - circulatory condition
antifungalciclo,Diagnosis of a fungal infection of the lower extremities - diabetes
antifungalciclo,Other
antifungalclio,Other
antifungalclio,Diagnosis of a fungal infection of the lower extremities - other
antifungalclio,Diagnosis of a fungal infection of the lower extremities - circulatory condition
antifungalclio,Diagnosis of a fungal infection of the lower extremities - diabetes
antifungalclot,Other
antifungalclot,Diagnosis of a fungal infection of the lower extremities - diabetes
antifungalclot,Diagnosis of a fungal infection of the lower extremities - other
antifungalclot,Diagnosis of a fungal infection of the lower extremities - circulatory condition
antifungalketo,Other
antifungalketo,Diagnosis of a fungal infection of the lower extremities - other
antifungalketo,Diagnosis of a fungal infection of the lower extremities - circulatory condition
antifungalketo,Diagnosis of a fungal infection of the lower extremities - diabetes
antifungalmico,Diagnosis of a fungal infection of the lower extremities - other
antifungalmico,Diagnosis of a fungal infection of the lower extremities - circulatory condition
antifungalmico,Diagnosis of a fungal infection of the lower extremities - diabetes
antifungalmico,Other
apomorphine,"For the acute, intermittent treatment of patients with advanced Parkinson's disease"
apomorphine,Other
aprepitant,For the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy (HEC).
aprepitant,Other
ARBcand,Patient has experienced intractable cough
ARBcand,Patient has experienced angioedema
ARBcand,Other
ARBepro,Other
ARBepro,Patient has experienced intractable cough on an Angiotensin Converting Enzyme Inhibitor (ACE-I): ALL reference ARBs must have been unsucessfully tried
ARBepro,Patient has experienced angioedema on an Angiotensin Converting Enzyme Inhibitor (ACE-I): ALL reference ARBs must have been unsucessfully tried
ARBirbe,Patient has experienced angioedema
ARBirbe,Other
ARBirbe,Patient has experienced intractable cough
ARBlosa,Patient has experienced intractable cough
ARBlosa,Other
ARBlosa,Patient has experienced angioedema
ARBolme,Patient has experienced intractable cough
ARBolme,Patient has experienced angioedema
ARBolme,Other
ARBtelm,Patient has experienced intractable cough
ARBtelm,Other
ARBtelm,Patient has experienced angioedema
ARBvals,Other
ARBvals,Patient has experienced angioedema
ARBvals,Patient has experienced intractable cough
aripip,Other
aripip,Other psychosis (not dementia related)
aripip,Schizophrenia
asenapine,Other
asenapine,Diagnosis of Bipolar I Disorder
Avonex,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
Avonex,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
Avonex,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
azet,For the cyclic treatment of chronic Pseudomonas aeruginosa infections in patients with moderate to severe cystic fibrosis
azet,Other
azet,A deteriorating clinical condition despite treatment with inhaled tobramycin
baclofen,Severe spasticity due to multiple sclerosis
baclofen,Severe spasticity due to spinal cord injury
baclofen,Other
benralizumab,severe eosinophilic asthma
benralizumab,other
benzydamine,"For the treatment of mucositis, ulcerative complications of chemotherapy"
benzydamine,Immunocompromised patients at risk of mucosal breakdown.
BPHDUTA,other
BPHDUTA,Diagnosis of benign prostatic hyperplasia (BPH)
BPHFINA,Diagnosis of benign prostatic hyperplasia (BPH)
BPHFINA,other
brex,Other psychosis (not dementia related)
brex,Schizophrenia
brex,Other
budcaps,Crohn's disease
budcaps,Other
budenema,Ulcerative Colitis
budenema,Other
bupre inj,Patient is an adult and have been induced and clinically stabilized on an equivalent of 8 mg to 24 mg of transmucosal buprenorphine-naloxone for a minimum of seven days
bupre inj,Exceptional coverage consideration
bupropiondepression,Other
bupropiondepression,Depression
cad,Other
cad,diagnosis of CAD and PAD
carv,Unable to take ACE-I (provide details):
carv,Concurrent therapy with an Angiotensin Converting Enzyme inhibitor (ACE-I)
carv,For treatment of stable symptomatic congestive heart failure:
CCBfelo,Other
CCBfelo,Complex patient requiring medications for co-existing chronic condition(s)
CCBfelo,"Treatment failure on optimal dose of, or intolerance to, amlodipine"
CCBnife,"Treatment failure on optimal dose of, or intolerance to, amlodipine"
CCBnife,Complex patient requiring medications for co-existing chronic condition(s)
CCBnife,Other
celecox,Psoriatic Arthritis
celecox,Rheumatoid Arthritis
celecox,Ankylosing Spondylitis
celecox,Lupus
celecox,Other
celecox,"Treatment failure on optimal doses of, or intolerance to, both ibuprofen and naproxen."
celecox,Gout
certo,Rheumatoid Arthritis
certo,Other
certo,Psoriatic Arthritis
certo,Ankylosing Spondylitis
chlorambucil,Other
chlorambucil,Lupus
chlorambucil,Vasculitis
chloroquine,Lupus
chloroquine,Other
chloroquine,Treatment of extraintestinal amebiasis
chloroquine,Rheumatoid Arthritis
ciproophthcipr,Failure or intolerance to first-line agents (e.g. aminoglycosides)
ciproophthcipr,Other
clobazam,Treatment of anxiety
clobazam,Other
codeine,For pain management in a specified chronic pain diagnosis
codeine,Other
codeine,Diagnosis of cancer
COPDaclid,Diagnosis of chronic obstructive pulmonary disease (COPD)
COPDaclid,Other
COPDaclidform,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted. 
COPDaclidform,Other
COPDflutsalm,Other
COPDflutsalm,Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted
COPDflutumecvila,Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted
COPDflutumecvila,Other
COPDflutvila,Other
COPDflutvila,Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted
COPDglyc,Other
COPDglyc,Diagnosis of chronic obstructive pulmonary disease (COPD) AND failureof both tiotropium and umeclidinium
COPDinda,Other
COPDinda,Diagnosis of COPD with a post-bronchodilator FEV1/FVC < 0.70 AND contraindication or intolerance to a long-acting muscarinic receptor antagonist (LAMAs)
COPDindaglyc,Other
COPDindaglyc,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA
COPDsalm,Diagnosis of COPD with a post-bronchodilator FEV1/FVC < 0.70 AND contraindication or intolerance to a long-acting muscarinic receptor antagonist (LAMAs)
COPDsalm,Other
COPDtiop,Other
COPDtiop,Diagnosis of chronic obstructive pulmonary disease (COPD) AND failureof both tiotropium and umeclidinium
COPDtiopolod,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA
COPDtiopolod,Other
COPDumecvila,Other
COPDumecvila,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA
cyclosporin,Extensive psoriasis involving at least 25% of body surface or having psoriasis area and severity index of at least 12
cyclosporin,Psoriasis of the palms and/or soles severe enough to interfere with daily living or work
cyclosporin,Treatment failure on topical corticosteroid
cyclosporin,Nephrotic syndrome
cyclosporin,Other
cyclosporin,Ultraviolet-B light or oral or topical methoxsalen plus ultraviolet-A ligh
cyclosporin,Topical therapy with corticosteroids
cyclosporin,Severe ocular inflammatory disease
cyclosporin,Rheumatoid Arthritis
cyclosporin,UVB/UVA light therapy is not available
cyproinj,Indication of need to reduce aggressive sexual drive
cyproinj,Other
cyprooral,Other
cyprooral,Indication of need to reduce aggressive sexual drive
dalteparin,Treatment of venous thromboembolism associated with cancer
dalteparin,Treatment of venous thromboembolism
dalteparin,Other
dalteparin,Prophylaxis of venous thromboembolism
deferprox,Congenital disease
deferprox,Other
deferprox,Acquired disease
defersirox,Congenital disease
defersirox,Acquired disease
defersirox,Other
denosacla,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - other
denosacla,Other
denosacla,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - immune-mediated hypersensitivity reaction to oral bisphosphonates
denosacla,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia
denosprol,Other
denosprol,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - immune-mediated hypersensitivity reaction to oral bisphosphonates
denosprol,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia
denosprol,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - other
desmopressin,Other
desmopressin,Treatment of diabetes insipidus
diclo,Ankylosing Spondylitis
diclo,Other
diclo,Rheumatoid Arthritis
diclo,Lupus
diclo,Psoriatic Arthritis
diclo,Gout
diclomiso,Gout
diclomiso,Lupus
diclomiso,Other
diclomiso,Ankylosing Spondylitis
diclomiso,Psoriatic Arthritis
diclomiso,Rheumatoid Arthritis
dienogest,Experienced treatment failure on combined hormonal contraceptives
dienogest,For the management of pelvic pain associated with endometriosis
dienogest,Unable to use combined hormonal contraceptives
dienogest,Other
dimethylfumarate,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
dimethylfumarate,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
dimethylfumarate,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
DOACapix,Non-valvular Atrial Fibrillation
DOACapix,Other
DOACapix,Deep Vein Thrombosis (DVT)
DOACapix,Pulmonary Embolism (PE)
DOACriva,Other
DOACriva,Non-valvular atrial fibrillation
DOACriva,Deep vein thrombosis (DVT)
DOACriva,Pulmonary embolism (PE)
dorzolamide,Diagnosis of ocular hypertension and open-angle glaucoma in patients with a demonstrated allergy to preservative
dorzolamide,Other
DPP4lina,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea
DPP4lina,Type 2 diabetes - Dual therapy of metformin and an insulin
DPP4lina,Other
DPP4lina,Type 2 diabetes - trial of one agent
DPP4saxa,Other
DPP4saxa,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea
DPP4saxa,Type 2 diabetes - Dual therapy of metformin and an insulin
DPP4saxa,Type 2 diabetes - trial of one agent
dronedarone,Other
dronedarone,"For long-term rhythm control of atrial fibrillation (AF) who successfully achieved rhythm control on amiodarone, but who have developed intolerable adverse effects to amiodarone (NOT including liver adverse effects)"
duloxetine,Other
duloxetine,For the treatment of neuropathic pain
duodopa,Patient experiences severe disability despite having tried frequent dosing of levodopa
duodopa,For the management of severe cases of advanced idiopathic Parkinson's Disease
edaravone,Initial Request - Diagnosis of probable amyotrophic lateral sclerosis (ALS) or definite ALS
edaravone,Renewal Request
edaravone,Other
enoxaparin,Prophylaxis of venous thromboembolism
enoxaparin,Other
enoxaparin,Treatment of venous thromboembolism
entacapone,Parkinson's Disease - As adjunct therapy for patients with an inadequate response after alterations of levodopa/carbidopa doses.
entacapone,Other
entacapone,Other
entecavir,Other
entecavir,Chronic Hepatitis B
Entresto,Other
Entresto,Patient has heart failure with New York Heart Association (NYHA) Class II to III symptoms - despite at least four weeks of treatment at the optimum stable dose of a beta-blocker and other recommended therapies
epclusa,lung transplant recipient
epclusa,Genotype 3 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,liver transplant recipient
epclusa,Mixed genotype - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Mixed genotype - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genotype 6 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 6 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genotype 5 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 5 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genotype 4 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 4 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genptype 3 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 2 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 2 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genotype 1 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 1 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epoprostenol,Other
epoprostenol,"As monotherapy, for the treatment of WHO/NYHA functional class IV PAH and inadequate response to non-prostanoid therapies"
epoprostenol,"As monotherapy, for the treatment of WHO/NYHA functional class IV PAH and contraindication to the non-prostanoid therapies"
eslicarbazepine,Other
eslicarbazepine,Adjunctive therapy for partial-onset seizures in adults after other medications have been tried without success
estraderm,For indications of menopausal and post-menopausal symptoms - Extreme intolerance to oral preparations
estraderm,For indications of menopausal and post-menopausal symptoms - Diagnosis of severe liver disease
estraderm,For indications of menopausal and post-menopausal symptoms - other
estraderm,Other
etanbiosim,Rheumatoid Arthritis
etanbiosim,Plaque Psoriasis
etanbiosim,Psoriatic Arthritis
etanbiosim,Other
etanbiosim,Ankylosing Spondylitis
evo,"Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Dutch Lipid Network criteria"
evo,"Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Genetic testing"
evo,Renewal Request - LDL-C is reduced by at least 40% from the LDL prior to treatment with evolocumab
evo,"Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Simon Broome criteria"
ezetimibe,Other
ezetimibe,Patient has a diagnosis of hypercholesterolemia.
febuxostat,Other
febuxostat,For the reduction of serum uric acid levels in patients with gout who demonstrate an immune-mediated hypersensitivity reaction to allopurinol
fent patch,For pain management in a specified chronic pain diagnosis
fent patch,Diagnosis of cancer
fent patch,Other
fidaxomicin,treatment of C. Difficile - documented allergy
fidaxomicin,treatment of C. Difficile - severe intolerance to oral vancomycin
fidaxomicin,treatment of C. Difficile - failure of oral vancomycin AND when retreatment with vancomycin is not an option AND when the patient is at high risk of hospitalization
fidaxomicin,Other
filgrastim,Post-BMT to stimulate bone marrow engraftment
filgrastim,Post-BMT for rescue of failure to engraft
filgrastim,Myelodysplastic disorders or aplastic anemia awaiting bone marrow transplantation
filgrastim,Chronic benign cyclical neutropenia
filgrastim,For SECONDARY prophylaxis of febrile neutropenia in cancer patients receiving potentially CURATIVE myelosuppressive chemotherapy
filgrastim,For PRIMARY prophylaxis of febrile neutropenia in cancer patients receiving potentially CURATIVE myelosuppressive chemotherapy regimens
filgrastim,Cancer patients undergoing peripheral blood progenitor cell (PBPC) collection and therapy
filgrastim,For rescue of prolonged febrile neutropenia following chemotherapy
fingolimod,other
fingolimod,As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis
fluconsolids,Exceptions on an individual basis for fungal infections resistant to first-line medications.
fluconsolids,Immunocompromised patient
fluconsolids,Other
gabapentin,Diagnosis of Bipolar Disorder
gabapentin,Other
glatiramer,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
glatiramer,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
glatiramer,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
gliclazide,"Treatment failure or intolerance to at least one other sulfonylurea drug (e.g., glyburide, tolbutamide) at adequate doses."
gliclazide,Other
golim,Ankylosing Spondylitis
golim,Psoriatic Arthritis
golim,Other
golim,Rheumatoid Arthritis
goserelin,Patient has a diagnosis of endometriosis
goserelin,Other
H2Bcime,Other
H2Bcime,"Treatment failure on prescription dose of, or intolerance to, ranitidine"
H2Bfamo,Other
H2Bfamo,"Treatment failure on prescription dose of, or intolerance to, ranitidine"
H2Bniza,Other
H2Bniza,"Treatment failure on prescription dose of, or intolerance to, ranitidine"
harvoni,Genotype 1 - Treatment-naive or treatment-experienced² with decompensated cirrhosis³: (with RBV) for 12 weeks.
harvoni,"Genotype 1 - Liver transplant recipients, treatment-naive or treatment-experienced² with no cirrhosis or with compensated cirrhosis¹:  (with RBV) for 12 weeks."
harvoni,Genotype 1 - Treatment-experienced² with compensated cirrhosis¹: 24 weeks.
harvoni,"Genotype 1 - HIV/HCV-1 co-infected, treatment-naive or treatment-experienced² with no cirrhosis or with compensated cirrhosis¹: 12 weeks."
harvoni,Genotype 1 - Treatment-experienced² with no cirrhosis:  12 weeks.
harvoni,Genotype 1 - Treatment-naive with no cirrhosis (including advanced fibrosis stage ≥ 3) or with compensated cirrhosis¹: 12 weeks.
harvoni,"Genotype 1 - Treatment-naive, mono-HCV infected, fibrosis stage < F3 and HCV RNA < 6 million IU/mL (only considered for non-cirrhotic patients): 8 weeks."
Humira,Ulcerative Colitis
Humira,Polyarticular Juvenile Idiopathic Arthritis
Humira,Moderate to Severe Active Crohn's
Humira,Fistulizing Crohn's
Humira,Plaque Psoriasis
Humira,Hidradenitis Suppurativa
Humira,Other
Humira,Psoriatic Arthritis
Humira,Ankylosing Spondylitis
Humira,Rheumatoid Arthritis
hydromorph50inj,Other
hydromorph50inj,"Relief of severe pain in patients who require subcutaneously, intravenously or intramuscularly administered opioids in doses or concentrations higher than those usually needed"
hydromorphSR,Other
hydromorphSR,Pain management in a specified chronic pain (including cancer pain) diagnosis AND regular release dosage forms of hydromorphone
hydromorphSR,Pain management in a specified chronic pain (including cancer pain) diagnosis AND sustained release preparations of morphine
hydroxyurea,Patient has a diagnosis of pustular psoriasis 
hydroxyurea,Other
hydroxyzine,For the treatment of anxiety
hydroxyzine,Other
icat,Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE) - type I
icat,Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE) - type II
icat,Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE) - other
icat,Renewal Request - Patient is limited to a single dose for self-administration per attack
incobot,For the treatment of blepharospasm
incobot,For the treatment of cervical dystonia of a predominantly rotational form (Spasmodic Torticollis)
incobot,For the treatment of post-stroke spasticity of the upper limb
incobot,Other
indapamide,Treatment failure or intolerance to a thiazide diuretic
indapamide,Other
inflix,Moderate to Severe Active Crohn's
inflix,Fistulizing Crohns
inflix,Ulcerative Colitis
inflix,Rheumatoid Arthritis
inflix,Ankylosing Spondylitis
inflix,Psoriatic Arthritis
inflix,Plaque Psoriasis
inflix,Other
interferonA,"Chronic Hepatitis B, non-cirrhosis"
interferonA,Other
interferonB1B,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
interferonB1B,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
interferonB1B,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
interferonB1B,As monotherapy for secondary progressive multiple sclerosis (SPMS) - initial
interferonB1B,As monotherapy for secondary progressive multiple sclerosis (SPMS) - renewal
interferonB1B,As monotherapy for secondary progressive multiple sclerosis (SPMS) - switch
isavuconazole,For the treatment of Invasive Mucormycosis (IM) in adults when prescribed by infectious disease specialist and if a patient is established on isavuconazole in hospital
isavuconazole,Other
ismn,Diagnosis of unstable angina
ismn,Experienced treatment failure on optimal dose of isosorbide dinitrate (ISDN)
ismn,Other
ismn,Experienced intolerance to isosorbide dinitrate (ISDN)
itraconazole,Immunocompromised patient
itraconazole,Pulse treatment for severe onychomycosis with functional disability
itraconazole,Other
ivabradine,"NYHA class II or III symptoms that have persisted despite at least four weeks of treatment at the optimum stable dose of a B-blocker, an aldosterone antagonist AND an ACEI or an ARB"
ivabradine,Other
ivabradine,Patient has stable heart failure with New York Heart Association Class II or III symptoms
ixekiz,Other
ixekiz,Plaque Psoriasis
LABAflutsalm,Other
LABAflutsalm,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.
LABAflutvila,Other
LABAflutvila,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.
LABAform,Other
LABAform,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.
LABAformbude,Other
LABAformbude,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.
LABAformmom,Other
LABAformmom,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.
LABAsalm,Other
LABAsalm,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid
lacolaco,Other
lacolaco,For adjunctive therapy (to be used in combination with at least ONE other anti-epileptic drug) for partial-onset seizures
lacopera,At least four other anti-epileptic medications have been tried without success
lacopera,Other
lacopera,For adjunctive therapy (to be used in combination with at least ONE other anti-epileptic drug) for partial-onset seizures
lactulose,Treatment of liver failure
lactulose,Treatment of portal systemic encephalopathy
lactulose,Other
LAinsulinbasa,Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced unexplained nocturnal hypoglycemia at least once a month despite optimal management
LAinsulinbasa,"Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced or continues to experience severe, systemic or local allergic reaction to existing insulin treatment"
LAinsulinbasa,Patient has a contraindication to NPH insulin
LAinsulinbasa,Other
Lainsulindete,Patient has a contraindication to NPH insulin
Lainsulindete,"Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced or continues to experience severe, systemic or local allergic reaction to existing insulin treatment"
Lainsulindete,Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced unexplained nocturnal hypoglycemia at least once a month despite optimal management
Lainsulindete,Other
lamivudine,Chronic Hepatitis B
lamivudine,Other - Hepatitis B reactivation prophylaxis while on immunosuppressants
lamivudine,Other
LBMdiph,For the treatment of diarrhea due to a specified chronic illness
LBMdiph,Other
LBMlope,For the treatment of diarrhea due to a specified chronic illness
LBMlope,Other
leflunomide,Rheumatoid Arthritis
leflunomide,Other
leuprolide,Diagnosis indicating need to reduce sexual drive
leuprolide,Other
leuprolide,Diagnosis of precocious puberty
leuprolide,Diagnosis of endometriosis
levetiracetam,Diagnosis of epilepsy
levetiracetam,Other
linezolid,Treatment of vancomycin resistant enterococcus (VRE) infections
linezolid,Other
linezolid,Treatment of methicillin-resistant staphylococcus aureus (MRSA) in patients who are unresponsvie to or intolerant of injectable vancomycin
Maintenaarip,For management of manifestations of related psychotic disorders (not dementia-related)
Maintenaarip,For management of manifestations of schizophrenia
Maintenaarip,Other
Maintenapalisust,Other
Maintenapalisust,"For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled"
Maintenapalisust,For management of manifestations of schizophrenia
Maintenapalisust,For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia
Maintenapalisust,For management of manifestations of related psychotic disorders (not dementia-related) - with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations
Maintenapalitrin,For management of manifestations of schizophrenia
Maintenapalitrin,"For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled"
Maintenapalitrin,Other
Maintenapalitrin,For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia
Maintenapalitrin,For management of manifestations of related psychotic disorders (not dementia-related) - with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations
Maintenarisp,"For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled"
Maintenarisp,For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia
Maintenarisp,For management of manifestations of related psychotic disorders (not dementia-related) - history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations
Maintenarisp,Other
Maintenarisp,For management of manifestations of schizophrenia
maviret,Genotype 5 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.
maviret,genotype 6 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 6 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.
maviret,Genotype 5 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.
maviret,genotype 5 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 4 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.
maviret,Genotype 4 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.
maviret,genotype 4 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 3 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.
maviret,Genotype 3 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.
maviret,genotype 3 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 2 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.
maviret,Genotype 2 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.
maviret,genotype 2 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,"Genotype 1 - Previously treated⁴ with an NS5A inhibitor-containing regimen, but NS3/4A protease inhibitor treatment-naive: 16 weeks"
maviret,"Genotype 1 - Previously treated³ with an NS3/4A protease inhibitor-containing regimen, but NS5A inhibitor treatment-naive: 12 weeks."
maviret,Genotype 1 - Treatment-experienced¹ with compensated cirrhosis²: 12 weeks
maviret,Genotype 1 - Treatment-experienced¹ with no cirrhosis: for 8 weeks
maviret,Genotype 1 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 6 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.
maviret,kidnet transplant recipient
maviret,heart transplant recipient
meloxicam,"Treatment failure on optimal doses of, or intolerance to, both ibuprofen and naproxen"
meloxicam,Other
meloxicam,Rheumatoid Arthritis
meloxicam,Psoriatic Arthritis
meloxicam,Ankylosing Spondylitis
meloxicam,Gout
meloxicam,Lupus
mepolizumab,other
mepolizumab,severe eosinophilic asthma
mercaptopurine,Crohn's disease
mercaptopurine,Other
mercaptopurine,Ulcerative Colitis
mercaptopurine,Autoimmune hepatitis
mercaptopurine,Inflammatory bowel disease
methotrexatePFsyringe,Other
methotrexatePFsyringe,"Treatment of rheumatoid arthritis, when the patient demonstrates failure on or intolerance to oral methotrexate"
methotrexateVial,"Treatment of rheumatoid arthritis, when the patient demonstrates failure on or intolerance to oral methotrexate"
methotrexateVial,Other
miniMed,Other form of diabetes (please specify):
miniMed,Type 1 diabetes
mmf,Autoimmune hepatitis
mmf,Bullous pemphigold
mmf,Other
modafinil,Treatment of narcolepsy
modafinil,Other
mometNS,Diagnosis of allergic rhinitis in child 3-11 years old
mometNS,Other
nabumetone,Lupus
nabumetone,Psoriatic Arthritis
nabumetone,Ankylosing Spondylitis
nabumetone,Gout
nabumetone,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
nabumetone,Other
nabumetone,Rheumatoid Arthritis
nadroparin,Prophylaxis of venous thromboembolism
nadroparin,Treatment of venous thromboembolism
nadroparin,Other
naproEC,Psoriatic Arthritis
naproEC,Ankylosing Spondylitis
naproEC,Gout
naproEC,Lupus
naproEC,"Treatment failure on optimal dose, or intolerance to, at least one of enteric-coated ASA, ibuprofen, or naproxen"
naproEC,Other
naproEC,Rheumatoid Arthritis
natalizumab,As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis
natalizumab,other
nebulesbude,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination
nebulesbude,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece
nebulesbude,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily
nebulesbude,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.
nebulesbude,Other
nebulescrom,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices
nebulescrom,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece
nebulescrom,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily
nebulescrom,Other
nebulescrom,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.
nebulesipra,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece
nebulesipra,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices
nebulesipra,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber
nebulesipra,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily
nebulesipra,Other
nebulesiprasalb,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices
nebulesiprasalb,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily
nebulesiprasalb,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber
nebulesiprasalb,Other
nebulesiprasalb,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece
nebulessalb,Other
nebulessalb,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece
nebulessalb,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices
nebulessalb,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily
nebulessalb,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.
netupitant,For the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy in combination with dexamethasone
netupitant,Other
nintedanib,Initial - For the treatment of adult patients who have a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF)
nintedanib,First renewal - idiopathic pulmonary fibrosis (IPF)
nintedanib,Second and subsequent renewal - idiopathic pulmonary fibrosis (IPF)
nintedanib,Other
nitisinone,hereditary tyrosinemia type 1 (HT-1) - for patients identified through newborn screening
nitisinone,hereditary tyrosinemia type 1 (HT-1) - for patients identified through prenatal genetic testing
NSAIDdiflu,Other
NSAIDdiflu,Lupus
NSAIDdiflu,Rheumatoid Arthritis
NSAIDdiflu,Gout
NSAIDdiflu,Ankylosing Spondylitis
NSAIDdiflu,Psoriatic Arthritis
NSAIDflur,Lupus
NSAIDflur,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
NSAIDflur,Other
NSAIDflur,Diagnosis of gout
NSAIDflur,Ankylosing Spondylitis
NSAIDflur,Psoriatic Arthritis
NSAIDflur,Rheumatoid Arthritis
NSAIDindo,Other
NSAIDindo,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
NSAIDindo,Lupus
NSAIDindo,Gout
NSAIDindo,Ankylosing Spondylitis
NSAIDindo,Psoriatic Arthritis
NSAIDindo,Rheumatoid Arthritis
NSAIDketo,Other
NSAIDketo,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
NSAIDketo,Lupus
NSAIDketo,Gout
NSAIDketo,Ankylosing Spondylitis
NSAIDketo,Psoriatic Arthritis
NSAIDketo,Rheumatoid Arthritis
NSAIDketoSR,Rheumatoid Arthritis
NSAIDketoSR,Psoriatic Arthritis
NSAIDketoSR,Ankylosing Spondylitis
NSAIDketoSR,Gout
NSAIDketoSR,Lupus
NSAIDketoSR,"Treatment failure on optimal dose, or intolerance to, at least one of enteric-coated ASA, ibuprofen, or naproxen"
NSAIDketoSR,Other
OBE,Obeticholic acid will be used as monotherapy in patient
OBE,Other
OBE,Obeticolic acid will be used in combination with ursodeoxycholic acid (UDCA)
OBE,For treatment of adult patient with confirmed diagnosis of primary billary cholangitis (PBC) - liver biopsy results consistent with PBC
OBE,For treatment of adult patient with confirmed diagnosis of primary billary cholangitis (PBC) - positive antimitochondrial antibodies
ocrelizumab,As treatment for Early Primary Progressive Multiple Sclerosis (PPMS)
ocrelizumab,Other
ofloxacin,Failure or intolerance to first-line agents (e.g. aminoglycosides)
ofloxacin,Other
olan,Other
olan,Diagnosis of Schizophrenia AND treatment failure or intolerance to at least one other specified anti-psychotic agent
olan,"Diagnosis of Bipolar I disorder AND treatment failure or intolerance to lithium, carbamazepine or divalproex sodium AND treatment failure or intolerance to at least one other specified anti-psychotic agent"
olan,Diagnosis of other psychosis (not dementia related) AND treatment failure or intolerance to at least one other specified anti-psychotic agent
omnipod,Other form of diabetes (please specify):
omnipod,Type 1 diabetes
onabot,Treatment of strabismus
onabot,Treatment of equinus foot deformity due to spasticity in pediatric Cerebral Palsy patients 2 years of age or older.
onabot,"Treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) associated with multiple sclerosis or subcervical spinal cord injury,"
onabot,Treatment of overactive bladder (OAB) in adult patients
onabot,Treatment of blepharospasm.
onabot,Treatment of spasmodic torticollis
onabot,"Treatment of focal spasticity, including the treatment of upper limb spasticity associated with stroke in adults."
onabot,Other
otherInsulinPumpNotApproved,Other form of diabetes (please specify):
otherInsulinPumpNotApproved,Type 1 diabetes
Pagetsalen,Diagnosis of Paget's disease
Pagetsalen,Other
Pagetsrise,other
Pagetsrise,diagnosis of Paget's disease
PAH1,For the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)
PAH1,Other
PAH2,"As monotherapy, for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)"
PAH2,"As monotherapy, for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH)"
PAH4,For the treatment of functional class IV pulmonary arterial hypertension (PAH) - contraindication to the non-prostanoid therapies
PAH4,Other
PAH4,For the treatment of functional class IV pulmonary arterial hypertension (PAH) - inadequate response to the non-prostanoid therapies
PAH5,Idiopathic pulmonary arterial hypertension (PAH)
PAH5,PAH associated with connective tissue disorders
PAH5,PAH associated with congenital heart disease
PAH5,Adult patient with World Health Organization / New York Heart Association functional class III PAH whose symptoms are inadequately controlled with a phosphodiesterase-type 5 inhibitor and endothelin receptor antagonist:
PAH5,Other
PAH5,Heritable PAH
pamidronate,Diagnosis indicating bone metastases associated with cancer (except breast cancer)
pamidronate,Other
pentazocine,Other
pentazocine,Patient has experienced treatment failure or intolerance to at least two identified opioids
pentazocine,For pain management in a specified pain diagnosis
pimecro,Other
pimecro,Diagnosis of eczema - refractory to three months of potent topical corticosteroid therapy
pimecro,Diagnosis of eczema - intolerant to topical corticosteroid treatment
pirfenidone,Initial - For the treatment of adult patients who have a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF)
pirfenidone,First renewal - idiopathic pulmonary fibrosis (IPF)
pirfenidone,Second and subsequent renewal - idiopathic pulmonary fibrosis (IPF)
pirfenidone,Other
piroxicam,Lupus
piroxicam,Rheumatoid Arthritis
piroxicam,Psoriatic Arthritis
piroxicam,Ankylosing Spondylitis
piroxicam,Gout
piroxicam,Other
piroxicam,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
prami,For the treatment of idiopathic Parkinson's disease - other
prami,Other
prami,For the treatment of idiopathic Parkinson's disease - receiving treatment with levodopa and requires additional adjunctive therapy
prami,For the treatment of idiopathic Parkinson's disease - cannot tolerate or has contraindications to levodopa
propranolol,renewal - proliferating infantilei hemangioma requiring systemic therapy
propranolol,initial - proliferating infantilei hemangioma requiring systemic therapy
prostaglandin,Other
prostaglandin,Erectile dysfunction that occurs as a result of vascular or neurological damage that precludes adequate filling of the sinusoidal spaces
ralox,"Clinical or radiographically-documented fracture due to osteoporosis - intolerable side effects to a minimum 1 month trial of oral bisphosphonates, alendronate or risedronate"
ralox,"Clinical or radiographically-documented fracture due to osteoporosis - unsatisfactory clinical response, defined as a new fragility fracture after 1 year adherence to alendronate or alendronate plus cholecalciferol or risedronate therapy"
ralox,Other
Rebif,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
Rebif,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
Rebif,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
rifaximin,Other
rifaximin,Reducing the risk of overt hepatic encephalopathy (HE) recurrence - hospitalized with HE associated with cirrhosis of the live
rifaximin,Reducing the risk of overt hepatic encephalopathy (HE) recurrence - unable to achieve adequate control despite taking the maximum tolerated dose of lactulose
risan,Plaque Psoriasis
risan,Other
ritux,Rheumatoid Arthritis
ritux,Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
ritux,Other
ritux,Multiple Sclerosis
ropinirole,For the treatment of idiopathic Parkinson's disease - receiving treatment with levodopa and requires additional adjunctive therapy
ropinirole,For the treatment of idiopathic Parkinson's disease - cannot tolerate or has contraindications to levodopa
ropinirole,For the treatment of idiopathic Parkinson's disease - other
ropinirole,Other
rotig,Other
rotig,"For the treatment of advanced stage Parkinson’s disease, when the patient is receiving treatment with levodopa AND requires additional adjunctive therapy"
rufinamide,For the treatment of Lennox-Gastaut syndrome (LGS)
rufinamide,Other
sarilumab,Rheumatoid Arthritis
sarilumab,Other
secukinumab,Other
secukinumab,Plaque Psoriasis
secukinumab,Psoriatic Arthritis
secukinumab,Ankylosing Spondylitis
semaglutide,Other
semaglutide,Type 2 diabetes - trial of one agent
semaglutide,Type 2 diabetes - Dual therapy of metformin and an insulin
semaglutide,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea
SGLT2,Type 2 diabetes - trial of one agent
SGLT2,Other
SGLT2,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea
SGLT2,Type 2 diabetes - Dual therapy of metformin and an insulin
sildenafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)
sildenafil,Other
sildenafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH)
solifen,Who have developed SEVERE intolerance to immediate-release oxybutynin requiring discontinuation of oxybutynin
solifen,Overactive Bladder Syndrome
somatropin,Other
somatropin,For true growth hormone deficiency 
somatropin,For chronic renal insufficiency
sovaldi,genotype 2 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: (with RBV) for 12 weeks.
sovaldi,genotype 3 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: (with RBV) for 24 weeks.
statinsfluv,Results of trial to rosuvastatin - Other
statinsfluv,Other
statinsfluv,Results of trial to rosuvastatin - Intolerance
statinsfluv,Results of trial to rosuvastatin - Treatment failure
statinsfluv,Results of trial to atorvastatin - Other
statinsfluv,Results of trial to atorvastatin - Treatment failure
statinsfluv,Results of trial to atorvastatin - Intolerance
statinslova,Other
statinslova,"Treatment failure on optimal doses of, OR specified intolerance to BOTH reference drugs: atorvastatin AND rosuvastatin"
statinsprav,Other
statinsprav,"Treatment failure on optimal doses of, OR specified intolerance to BOTH reference drugs: atorvastatin AND rosuvastatin"
statinssimv,Results of trial to rosuvastatin - Intolerance
statinssimv,Results of trial to atorvastatin - Intolerance
statinssimv,Results of trial to atorvastatin - Other
statinssimv,Results of trial to rosuvastatin - Treatment failure
statinssimv,Results of trial to rosuvastatin - Other
statinssimv,Other
statinssimv,Results of trial to atorvastatin - Treatment failure
stiripen,Diagnosis of severe myoclonic epilepsy in infancy (Dravet syndrome)
stiripen,Other
sulindac,Rheumatoid Arthritis
sulindac,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
sulindac,Psoriatic Arthritis
sulindac,Ankylosing Spondylitis
sulindac,Other
sulindac,Lupus
sulindac,Gout
sumatrip,Other
sumatrip,Nausea and vomiting prevents swallowing oral preparations
sumatrip,Oral absorption is not practical.
tacrotopical,Other
tacrotopical,Diagnosis of eczema - is intolerant to topical corticosteroid treatment
tacrotopical,Diagnosis of eczema - is refractory to three months of potent topical corticosteroid therapy
tadalafil,Other
tadalafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH)
tadalafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)
tenofovir,Chronic Hepatitis B
tenofovir,Viral breakthrough while on treatment (adefovir experienced with persistant viremia and lamivudine resistance)
tenofovir,Viral breakthrough while on treatment (lamivudine resistance)
tenofovir,Other
tenofovir,Other - Hepatitis B reactivation prophylaxis while on immunosuppressant(s)
tenofovir,Other - patient is pregnant; to reduce vertical transmission of Hepatitis B
tenoxicam,Rheumatoid Arthritis
tenoxicam,Psoriatic Arthritis
tenoxicam,Ankylosing Spondylitis
tenoxicam,Gout
tenoxicam,Lupus
tenoxicam,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
tenoxicam,Other
terbinafine,Diagnosis of severe onychomycosis
terbinafine,Other
teriflunomide,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
teriflunomide,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
teriflunomide,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
testosteronecypi,Other
testosteronecypi,For the indication of documented low testosterone levels due to - AIDS-wasting syndrome
testosteronecypi,For the indication of documented low testosterone levels due to - surgery of pituitary gland
testosteronecypi,For the treatment of testosterone deficiency in - removal of pituitary gland
testosteronecypi,For the treatment of testosterone deficiency in - pituitary tumour
testosteronecypi,For the treatment of testosterone deficiency in - female-to-male transformation
testosteronecypi,For the treatment of testosterone deficiency in - undescended testes
testosteronecypi,For the treatment of testosterone deficiency in - orchiectomy
testosteronecypi,For the treatment of testosterone deficiency in - hypogonadism
testosteronecypi,For the treatment of testosterone deficiency in - Klinefelter's syndrome
testosteroneenan,For the treatment of testosterone deficiency in - orchiectomy
testosteroneenan,Other
testosteroneenan,For the indication of documented low testosterone levels due to - AIDS-wasting syndrome
testosteroneenan,For the indication of documented low testosterone levels due to - surgery of pituitary gland
testosteroneenan,For the treatment of testosterone deficiency in - removal of pituitary gland
testosteroneenan,For the treatment of testosterone deficiency in - pituitary tumour
testosteroneenan,For the treatment of testosterone deficiency in - female-to-male transformation
testosteroneenan,For the treatment of testosterone deficiency in - Klinefelter's syndrome
testosteroneenan,For the treatment of testosterone deficiency in - undescended testes
testosteroneenan,For the treatment of testosterone deficiency in - hypogonadism
testosteroneprop,For the indication of documented low testosterone levels due to - AIDS-wasting syndrome
testosteroneprop,For the indication of documented low testosterone levels due to - surgery of pituitary gland
testosteroneprop,For the treatment of testosterone deficiency in - removal of pituitary gland
testosteroneprop,For the treatment of testosterone deficiency in - pituitary tumour
testosteroneprop,Other
testosteroneprop,For the treatment of testosterone deficiency in - Klinefelter's syndrome
testosteroneprop,For the treatment of testosterone deficiency in - undescended testes
testosteroneprop,For the treatment of testosterone deficiency in - orchiectomy
testosteroneprop,For the treatment of testosterone deficiency in - hypogonadism
testosteroneprop,For the treatment of testosterone deficiency in - female-to-male transformation
tiaprofenic,Other
tiaprofenic,Psoriatic Arthritis
tiaprofenic,Ankylosing Spondylitis
tiaprofenic,Rheumatoid Arthritis
tiaprofenic,Diagnosis of gout
tiaprofenic,Lupus
tiaprofenic,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
ticag,Definite stent thrombosis after revascularization with percutaneous coronary intervention (PCI)
ticag,Recurrent ST or non-ST elevation myocardial infarction (STEMI or NSTEMI) after revascularization with percutaneous coronary intervention (PCI)
ticag,Recurrent unstable angina after revascularization with percutaneous coronary intervention (PCI)
ticag,Undergoing revascularization via percutaneous coronary intervention (PCI) secondary to ST or non-ST elevation myocardial infarction (STEMI or NSTEMI) or unstable angina
ticag,Other
ticlo,"Secondary prevention of coronary, cerebral and peripheral vascular occlusion and embolization - treatment failure with ASA"
ticlo,"Secondary prevention of coronary, cerebral and peripheral vascular occlusion and embolization - intolerance to ASA"
ticlo,Other
tinzaparin,Treatment of venous thromboembolism
tinzaparin,Other
tinzaparin,Prophylaxis of venous thromboembolism
tinzaparin,Treatment of venous thromboembolism associated with cancer
tizan,Diagnosis of spasticity - treatment failure with diazepam
tizan,Diagnosis of spasticity - intolerance to baclofen
tizan,Diagnosis of spasticity - treatment failure with baclofen
tizan,Diagnosis of spasticity - intolerance to diazepam
tizan,Other
tobi,Moderate to severe cystic fibrosis
tobi,Chronic pulmonary Pseudomonas aeruginosa infections
tobi,Other
tobi,Does not tolerate injectable forms of tobramycin to manage inhalation issues
tociliz,Polyarticular Juvenile Idiopathic Arthritis (pJIA)
tociliz,Systemic Juvenile Idiopathic Arthritis (sJIA)
tociliz,Other
tociliz,Rheumatoid Arthritis
tociliz,Giant Cell Arteritis (GCA)
tofacitinib,Rheumatoid Arthritis
tofacitinib,Ulcerative Colitis
tofacitinib,Other
tretinoin,Diagnosis of skin cancer
tretinoin,Diagnosis of acne
tretinoin,Other
Twynsta,Patient has experienced intractable cough or angioedema on an Angiotensin Converting Enzyme Inhibitor (ACE-I) AND is currently taking stable doses of both telmisartan and amlodipine
Twynsta,Other
TZDpio,Type 2 diabetes - Dual therapy of metformin and an insulin
TZDpio,Type 2 diabetes - trial of one agent
TZDpio,Other
TZDpio,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea
uste,Other
uste,Plaque Psoriasis
valganciclovir,Other
valganciclovir,"For the prophylaxis of cytomegalovirus (CMV) infection post stem cell transplant, in patients who test positive for CMV upon polymerase chain reaction (PCR) laboratory testing."
vancomycin,Treatment of symptomatic Clostridium Difficile Infection (CDI) - failed to respond to 4-6 days of oral metronidazole 500mg three times daily
vancomycin,"Treatment of symptomatic Clostridium Difficile Infection (CDI) - intolerant or cannot take metronidazole (e.g., pregnant women, alcoholism)"
vancomycin,symptomatic C. Difficile Infection (CDI) - symptoms of moderate to severe disease OR is experiencing a second disease recurrence (within 2-8 weeks of diagnosis of a previous episode)
vancomycin,Other
vancomycin,"symptomatic C. Difficile Infection (CDI) - initiated on vancomycin as an inpatient (e.g. in a hospital setting, nursing home, or long-term care facility) and requires continuation"
vedoIV,Fistulizing Crohn's
vedoIV,Moderate to Severe Active Crohn's
vedoIV,Ulcerative Colitis
voriconazole,Other
voriconazole,For continuation of hospital-initiated treatment of culture proven invasive candidiasis with documented resistance to fluconazole
voriconazole,For continuation of hospital-initiated treatment of invasive aspergillosis
vosevi,Genotype 2 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 3 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 3 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,"Genotype 3 - Exceptional Request: treatment naïve, F4 cirrhosis"
vosevi,Genotype 4 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 4 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 1 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 6 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks
vosevi,Unable to verify genotype - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Unable to verify genotype - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 2 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 1 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 5 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks
ypsoPump,Other form of diabetes (please specify):
ypsoPump,Type 1 diabetes
zepatier,Genotype 1a - treatment-naïve: 12 weeks
zepatier,Genotype 1b - treatment-naïve: 12 weeks
zepatier,Genotype 1a or 1b - treatment-experienced (prior relapsers): 12 weeks
zepatier,Genotype 1b - treatment-experienced (prior on-treatment virologic failures): 12 weeks
zepatier,Genotype 1a - treatment-experienced (prior on-treatment virologic failures): 16 weeks
zepatier,Genotype 4 - treatment-naïve: 12 weeks
zepatier,Genotype 4 - treatment-experienced (prior relapsers): 12 weeks
zepatier,Genotype 4 - treatment-experienced (prior on-treatment virologic failures) with RBV: 16 weeks
zip,Diagnosis of schizophrenia
zip,Other
zip,Other psychosis (not dementia related)
zopiclone,For the treatment of insomnia - HIV/AIDS
zopiclone,For the treatment of insomnia - identified psychiatric diagnosis
zopiclone,"For the treatment of insomnia - intolerant to, or failed on, at least three specified benzodiazepines"
zopiclone,"For the treatment of insomnia - intolerant to, or failed on, at least two specified benzodiazepines and one other specified hypnotic agent"
zopiclone,"For the treatment of insomnia - fragile, elderly patient"
zopiclone,For the treatment of insomnia - history of drug or alcohol addiction
zopiclone,Other
